Logo
x

Search category

Subscribe Now

HER-2 Breast Cancer

Mylan & Biocon Receive CHMP Recommendation to Ogivri (trastuzumab- biosimilar) for HER-2 Breast Cancer

Mylan & Biocon Receive CHMP Recommendation to Ogivri (trastuzumab- biosimilar) for HER-2 Breast Cancer

  • October 19, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.